Why Is CASI Pharmaceuticals, Inc. Ordinary Shares (CASI) Stock Down 68.7% Today?

CASI Pharmaceuticals (CASI) got absolutely crushed today. The stock tanked 68.7% to $0.2585 from a previous close of $0.80, bleeding out on a volume explosion of 3.77M shares traded — that's 193.8x the 30-day average. The catalyst: a buyout offer for the company's China business. For investors asking why is CASI stock down today, the answer lies in how the market interpreted this strategic transaction and what it signals about the company's future.

What's Driving CASI Stock Down Today

The headline sounds positive on the surface — CASI received a buyout offer for its China operations. But the market's reaction tells a different story.

The severity of the selloff suggests investors see the China business sale as a forced move, not a strategic win. Here's the reality: CASI's China operations represent a significant portion of the company's revenue and pipeline. Selling off that segment likely signals financial distress or an inability to operate independently in the critical Asian market. The stock's 68.7% crater in a single day indicates the market is repricing the company as a diminished entity.

This wasn't a surprise pop on good news — this was a panic liquidation. The 193.8x volume spike shows retail and institutional holders racing for the exits simultaneously. When a stock moves this violently on deal news, it typically means the deal terms are worse than expected, or the market questions whether the proceeds will be enough to keep the company viable.

CASI is a biopharmaceutical focused on cancer therapeutics, with EVOMELA (melphalan flufenamide) as a key product for conditioning treatment before autologous stem cell transplantation. Losing the China franchise — historically a growth engine for biotech companies — removes a critical revenue pillar and raises questions about the company's ability to fund ongoing R&D and clinical programs.

CASI Stock Key Levels to Watch

Current price action: $0.2585 (down from $0.80 close)

Today's range: $0.2368 — $0.3749. The stock printed a low of $0.2368, which could serve as fresh support if buyers step in. The intraday high of $0.3749 was likely hit early in the session before the full weight of selling pressure kicked in.

Critical support levels: $0.25 is a psychological floor. Below that, $0.15—$0.20 becomes the next zone. If the stock closes below $0.25, expect further capitulation tomorrow as stop losses trigger.

Resistance above: $0.35—$0.40 will face heavy selling. The $0.50 level marks the 50% retracement of today's move and should attract short covering if the stock stabilizes.

52-week context: With the stock now at $0.2585, it's likely near or at 52-week lows. This raises bankruptcy risk concerns, which could fuel additional selling if the company's cash position is weak.

Volume warning: Today's 3.77M shares was abnormal. Tomorrow's volume will be critical. If volume dries up above $0.30, that's a sign of capitulation and potential reversal. If volume stays heavy, more selling is likely.

What Analysts Say About CASI Stock

HC Wainwright & Co. maintained a Buy rating on CASI as of November 2023, but that rating is now essentially invalidated by today's move. A pre-buyout Buy rating doesn't account for the company being forced to divest its China business — the thesis has fundamentally changed.

The consensus before today likely reflected optimism around EVOMELA commercialization and China market expansion. That thesis is now in tatters. Any analyst report released before this morning is obsolete.

What matters now: Investors should wait for updated analyst commentary. The real question for analysts is whether the China buyout proceeds are enough to fund CASI's operations and pipeline through cash flow positivity. If the answer is no, the stock could crater further toward bankruptcy levels.

Current market cap sits at essentially zero based on the plunge. This means the market is pricing in significant distress risk.

What's Next for CASI Stock

Immediate catalyst: Company guidance on use of China buyout proceeds. CASI needs to immediately clarify: (1) How much cash will the deal generate? (2) What's the runway with that cash? (3) What programs will continue? (4) Is dilution coming via capital raise?

Bull case (thin): The China business buyout clears balance sheet issues and allows CASI to refocus on EVOMELA development in the U.S. market. If the deal proceeds are substantial enough to fund 2+ years of operations, CASI could stabilize at $0.40—$0.60 as a pure-play U.S. biotech.

Bear case (high probability): The China sale doesn't generate enough cash. The company needs to raise capital via dilutive equity offering or debt. CASI slides toward penny stock oblivion at $0.10—$0.15, or bankruptcy becomes the endgame. This is the market's current base case.

Next event to watch: Press release with deal terms and financial guidance. This will likely come within 24—72 hours. That's when the real capitulation or stabilization begins. Earnings won't matter here — corporate survival is the only thing on the table.

Frequently Asked Questions

Why is CASI stock down 68.7% today? CASI announced a buyout offer for its China business, which represents a significant revenue and growth component. The market interpreted the forced sale as a sign of financial distress rather than a strategic win, triggering panic selling on 193.8x average volume. Investors are now pricing in risk of further dilution or bankruptcy.

Is CASI stock a buy right now? At $0.2585, CASI is a high-risk, high-reward speculation only for traders with extremely high risk tolerance. This is not a suitable holding for most investors. Wait for company guidance on China deal proceeds and cash runway before considering any position. This article is educational analysis, not investment advice.

What is CASI stock's price target? Pre-deal analyst targets are invalidated. Any credible analyst covering CASI will need to reassess the company post-China sale. Expect targets to be slashed or coverage to be suspended pending deal details.

Should I panic sell my CASI shares? If you own CASI and didn't know about the China buyout before market open, you've already taken significant losses. Selling into this panic could lock in those losses. However, holding is also risky — the next 72 hours will determine whether the company survives independently or faces further distress. Set a hard stop loss and make a disciplined decision based on company guidance, not emotion.

What does this mean for CASI's drug pipeline? Losing the China franchise likely means delayed or abandoned programs focused on Asian markets. The company will shift focus entirely to U.S. and potentially European markets for EVOMELA and other therapeutics. This narrows the addressable market and reduces long-term revenue potential.

Bottom Line

CASI's 68.7% crash wasn't a typical earnings miss or clinical setback — it was a structural capitulation. The forced China business sale signals that CASI couldn't operate independently and needed to divest a crown jewel asset. The market is now repricing the company at distress valuations and pricing in material bankruptcy risk.

The next 72 hours are critical. Company guidance on deal proceeds, cash runway, and strategic direction will determine whether CASI stabilizes or continues sliding toward penny stock oblivion. Until that guidance hits, this is a spec position only — not a hedge fund portfolio holding.

Risk disclaimer: CASI is now trading at penny stock levels with extreme volatility, minimal liquidity outside market hours, and significant bankruptcy risk. Position sizing and risk management are non-negotiable. Any position should represent only capital you can afford to lose completely. This is educational analysis only and does not constitute investment advice.